Palvella Therapeutics, Inc. PVLA
147.06 USD +0.48 (+0.33%)
As ofNov 19, 2026, 12:26 PM EST
144.25 Day range 150.80
72.23 52-week range 179.95
- YTD
- +40.50%
- 1 year
- +51.75%
News
globenewswire.com Palvella Therapeutics Announces QTORIN™ Docetaxel, a New QTORIN™ Program for the Treatment of Extramammary Paget's Disease (EMPD) EMPD is a serious, rare, and life-threatening genital and perianal skin cancer QTORIN™ docetaxel builds on human clinical evidence of I.V. docetaxel in EMPD, with the potential to shift the treatment…
globenewswire.com Palvella Therapeutics to Host Webcast to Introduce New QTORIN™ Program Third product candidate from Palvella's QTORIN™ platform to be announced Live audiovisual webcast to take place tomorrow, Thursday, November 19, 2026, at 8:30 a.m. ET WAYNE, Pa.benzinga.com Leerink Partners Initiates Coverage On Palvella Therapeutics with Outperform Rating, Announces Price Target of $228 Leerink Partners analyst Jenny Gonzalez-Armenta initiates coverage on Palvella Therapeutics (NASDAQ:PVLA) with a Outperform rating and announces Price Target of $228.
defenseworld.net Palvella Therapeutics (NASDAQ:PVLA) Stock: Insider Jeffrey Martini Sells 6,250 Shares Palvella Therapeutics, Inc. (NASDAQ: PVLA - Get Free Report) insider Jeffrey Martini sold 6,250 shares of the stock in a transaction on Tuesday, November 10th. The stock was sold at an average price…benzinga.com Canaccord Genuity Maintains Buy on Palvella Therapeutics, Raises Price Target to $243 Canaccord Genuity analyst Whitney Ijem maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and raises the price target from $232 to $243.
benzinga.com Oppenheimer Maintains Outperform on Palvella Therapeutics, Raises Price Target to $232 Oppenheimer analyst Trevor Allred maintains Palvella Therapeutics (NASDAQ:PVLA) with a Outperform and raises the price target from $210 to $232.
benzinga.com Palvella Therapeutics Q3 2026 Earnings Call Transcript Palvella Therapeutics (NASDAQ:PVLA) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…benzinga.com Palvella Therapeutics Q3 EPS $(1.70) Beats $(1.82) Estimate Palvella Therapeutics (NASDAQ:PVLA) reported quarterly losses of $(1.70) per share which beat the analyst consensus estimate of $(1.82) by 6.59 percent. This is a 65.05 percent decrease over losses…
